# A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

> **NCT05568459** · — · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT05568459
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-17
- **Primary completion:** 2026-05-21
- **Final completion:** 2026-05-21
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05568459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05568459, "A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05568459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*